

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433

Status	RECRUITING
Phase	Phase 3
Sponsor	Axsome Therapeutics, Inc.
Enrollment	450 participants

Key Eligibility Criteria

Inclusion (3)

- Primary diagnosis of BED according to DSM-5 criteria.
- Provides written informed consent to participate in the study before the conduct of any study procedures.
- Male or female, aged 18 to 55 inclusive.

Exclusion (3)

- Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
- Unable to comply with study procedures.
- Medically inappropriate for study participation in the opinion of the investigator.

Locations (45 total)

Clinical Research Site, Encino, California, United States
Clinical Research Site, Garden Grove, California, United States
Clinical Research Site, Long Beach, California, United States
... and 42 more locations